Zydus Cadila has received tentative approval from the USFDA to market Ibrutinib Tablets, in the strengths of 140 mg, 280 mg, 420 mg and 560 mg. Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.
- Read more about Zydus Cadila receives tentative approval from the USFDA for Ibrutinib Tablets
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/zydus-cadila-receives-tentative-approval-from-the-usfda-for-ibrutinib-tablets
No comments:
Post a Comment